Description

10H,16H-Pyrrolo[2,1-C]Quinazolino[3,2-A][1,4]Benzodiazepine-10,16-Dione, 5B,6,7,8-Tetrahydro-4-Hydroxy-2,12-Dimethoxy-, (5Bs)- (9Ci) is a complex, high-purity heterocyclic compound of significant interest in advanced pharmaceutical research and development. This molecule serves as a critical synthetic intermediate or a key pharmacophore for the creation of novel therapeutic agents. It is primarily required by pharmaceutical R&D laboratories, contract research organizations (CROs), and fine chemical manufacturers engaged in cutting-edge drug discovery programs.

Application

• Pharmaceutical Intermediate: Serves as a key building block in the synthesis of novel benzodiazepine and quinazoline-derived active pharmaceutical ingredients (APIs).
• Medicinal Chemistry Research: Used as a core scaffold for structure-activity relationship (SAR) studies to develop new therapeutic candidates targeting central nervous system (CNS) disorders.
• Reference Standard: Employed as a high-purity analytical standard for method development, validation, and quality control in pharmaceutical analysis.
• Biochemical Tool Compound: Utilized in preclinical research to investigate specific biological pathways and receptor interactions.
• Process Chemistry Development: Acts as a critical intermediate in scaling up synthetic routes for potential drug candidates under Good Manufacturing Practice (GMP) conditions.

Basic Information

Product Name	10H,16H-Pyrrolo[2,1-C]Quinazolino[3,2-A][1,4]Benzodiazepine-10,16-Dione, 5B,6,7,8-Tetrahydro-4-Hydroxy-2,12-Dimethoxy-, (5Bs)- (9Ci)
CAS No.	232922-21-3
Molecular Formula	C22H19N3O6
Molecular Weight	421.41 g/mol
Synonyms	(5Bs)-5B,6,7,8-Tetrahydro-4-hydroxy-2,12-dimethoxy-10H,16H-pyrrolo[2,1-c]quinazolino[3,2-a][1,4]benzodiazepine-10,16-dione; 232922-21-3; Pyrroloquinazolinobenzodiazepinedione derivative; Tetrahydroxy-dimethoxy benzodiazepine fused heterocycle; 4-Hydroxy-2,12-dimethoxy-5b,6,7,8-tetrahydro-10H,16H-pyrrolo[2,1-c]quinazolino[3,2-a][1,4]benzodiazepine-10,16-dione; (5bS)-isomer of the above compound; 9CI indexed structure
EINECS	Contact for details

Quality Control

Our high-purity pharmaceutical-grade products undergo rigorous quality testing to ensure compliance with industry standards. We employ advanced analytical techniques including HPLC, NMR, and MS for identity confirmation and purity verification. Certificates of Analysis (COA) detailing batch-specific results are available upon request. Our quality management system supports development under cGMP guidelines for research use.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) in a dry, cool, and well-ventilated area. This compound is light-sensitive (store away from light) and may be hygroscopic (moisture-sensitive); therefore, containers should be kept sealed under an inert atmosphere if specified.

Specification

Item	Specification
Appearance	Off-white to light yellow powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 97.0%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.5%
Heavy Metals	≤ 20 ppm
Single Unknown Impurity (HPLC)	≤ 1.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.